[Form 4] Design Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Justin D. Gover, a director of Design Therapeutics, Inc. (DSGN), reported two option grants dated 09/09/2025. The filing shows awards of 30,000 and 15,833 stock options with an exercise price of $6.64 each, representing 45,833 underlying shares in total. The reporting form lists these as direct holdings. The filing includes vesting schedules: the 30,000-option award vests in equal monthly installments over 36 months following September 9, 2025, and the 15,833-option award vests in equal monthly installments over 12 months following September 9, 2025. The form was signed on behalf of the reporting person on 09/10/2025.

Positive

• Equity-based compensation disclosed showing alignment of the director's incentives with shareholder value through time-based vesting
• Clear vesting schedules (36 months and 12 months) that promote multi-year retention

Negative

• None.

Insights

Securities Analyst

TL;DR: Director received equity compensation totaling 45,833 options at $6.64, with multi-year vesting schedules.

The Form 4 documents routine equity awards to a company director rather than open-market trading or dispositions. The aggregate grant of 45,833 options creates potential future dilution only if exercised; the filing specifies direct ownership and structured vesting (36 months and 12 months), which aligns the director's incentives with multi-year retention. There are no cash proceeds or dispositions reported and no other compensatory details disclosed in this filing.

Corporate Governance Expert

TL;DR: Grants reflect standard retention-based compensation with defined monthly vesting schedules.

The disclosed awards appear to be time-based stock options issued to a director, with explicit monthly vesting over one and three years respectively. Such vesting schedules are common governance tools to promote continuity of service. The Form 4 does not disclose grant rationale, proportionality to total outstanding equity, or acceleration terms, limiting assessment of material governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gover Justin D.

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CA 92011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$6.64	09/09/2025		A		30,000		(1)	09/08/2035	Common Stock	30,000	$0	30,000	D
Stock option (right to buy)	$6.64	09/09/2025		A		15,833		(2)	09/08/2035	Common Stock	15,833	$0	15,833	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over 36 months following September 9, 2025.

2. The shares subject to the option will vest in equal monthly installments over 12 months following September 9, 2025.

	/s/ Mustapha Parekh, Attorney-in-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Justin D. Gover (DSGN) report on Form 4?

He reported two option grants dated 09/09/2025: 30,000 options and 15,833 options, for a total of 45,833 options.

What is the exercise price of the options reported by the director (DSGN)?

The exercise price is $6.64 per share for both option awards.

How do the reported options vest according to the Form 4?

The 30,000-option award vests monthly over 36 months following September 9, 2025; the 15,833-option award vests monthly over 12 months following September 9, 2025.

Are the reported option holdings direct or indirect?

The Form 4 lists these holdings as direct (D) beneficial ownership.

When was the Form 4 signed and filed?

The signature on the filing is dated 09/10/2025, executed by an attorney-in-fact.